Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis

Abstract: Atypical hemolytic uremic syndrome (aHUS), a life-threatening complement-mediated disorder, is now treatable with terminal complement inhibitors like eculizumab. Although effective, these therapies are costly, and increase susceptibility to infections, notably meningococcal disease, raisin...

Descripció completa

Dades bibliogràfiques

Autors principals:	Amy Hockman, Sydney Anuskiewicz, Emily Brennan, Saifur R. Chowdhury, Alexander Coltoff, Jacqueline N. Poston, Charles Greenberg, Benjamin Djulbegovic
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-12-01
Col·lecció:	Blood Advances
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2473952925004793
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!